Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that AstraZeneca Seroquel's first-line patient share grew two percent since last year's patient-level claims data analysis of prescribing trends in bipolar disorder. During this same time period other atypicals (with the exception of Pfizer's Geodon) lost first-line patient share which suggests that Seroquel's better penetration of first-line therapy came at the expense of others in the atypical class such as Bristol-Myers Squibb/Otsuka's Abilify and Eli Lilly's Zyprexa.

Although surveyed psychiatrists rate the overall attributes of Abilify higher than Seroquel/Seroquel XR, surveyed primary care physicians' assessment of these two agents is the opposite. Despite the advantage that surveyed psychiatrists give to Abilify over Seroquel on side-effect and safety attributes, Abilify's patient share is second to that of Seroquel in both first- and second-line therapy.

The new report entitled Treatment Algorithms in Bipolar Disorder also finds that although risperidone is now available in generics there is no clear evidence of its expanded uptake in early lines of therapy. Approximately 15 percent of surveyed physicians do not prescribe generic risperidone first-line and only one-third of surveyed physicians estimate that they prescribe generic risperidone first-line to more than half of their bipolar patients.

By pairing patient-level claims data with primary survey data, this report can be used to build patient-flow models and analyze the assumptions driving these models.

"Our analysis of patient-flow to Seroquel XR shows that 30 percent of the patients who take it after another agent previously received Seroquel, indicating that Seroquel XR continues to garner a major portion of its business in patients using it as a replacement for Seroquel. However, approximately one-third of surveyed physicians plan to use Seroquel XR more often in the first-line over the next two years, which suggests that competitors will need to position themselves to combat Seroquel XR's growing use as a first-line treatment," stated Madhuri Borde, Ph.D., product director of Treatment Algorithms at Decision Resources.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS Lifelink: Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Gisselle Morales                             Elizabeth Marshall   Decision Resources                           Decision Resources, Inc.   781-296-2691                                 781-296-2563   gmorales@dresources.com                      emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Gisselle Morales, Decision Resources, +1-781-296-2691,
gmorales@dresources.com, or Elizabeth Marshall, Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Skin and Skin Structure Infections Are the Second Most Common Diagnoses for Which an Antibiotic Is Used in the Hospital Setting

View Now